STOCK TITAN

Graphite Bio Inc - GRPH STOCK NEWS

Welcome to our dedicated news page for Graphite Bio (Ticker: GRPH), a resource for investors and traders seeking the latest updates and insights on Graphite Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Graphite Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Graphite Bio's position in the market.

Rhea-AI Summary
Graphite Bio, Inc. (GRPH) declared a special dividend of $1.03 per share in connection with the merger with Lenz Therapeutics, Inc. The payment is subject to the merger's closing and will be paid to stockholders of record as of March 18, 2024. The special dividend, not exceeding $60 million, will be paid on March 21, 2024, subject to merger conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.79%
Tags
dividends acquisition
-
Rhea-AI Summary
LENZ Therapeutics (LENZ) and Graphite Bio, Inc. (NASDAQ: GRPH) announced a definitive merger agreement to form a late clinical-stage biopharmaceutical company focused on treating presbyopia. The combined company is expected to trade on Nasdaq under the ticker symbol 'LENZ.' The merger includes a concurrent PIPE financing of $53.5 million, with the combined company anticipated to have approximately $225 million in cash or cash equivalents at close. The merger aims to advance LENZ's lead assets, LNZ100 and LNZ101, for presbyopia treatment, with a projected U.S. market opportunity exceeding $3 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
acquisition
-
Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced its financial results for Q3 2023. The company reported net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0%. Third quarter new and renewal lease executions totaled 2.3 million square feet. The company also received the GRESB Green Star designation for the twelfth consecutive year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
dividends earnings
Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced its financial results for Q3 2023. The company reported net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0%. Third quarter new and renewal lease executions totaled 2.3 million square feet. The company also received the GRESB Green Star designation for the twelfth consecutive year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
dividends earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.54%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
earnings
Graphite Bio Inc

Nasdaq:GRPH

GRPH Rankings

GRPH Stock Data

185.19M
2.38M
0.17%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About GRPH

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives